January 30, 2009 – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. FDA approved KAPIDEX (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis and the maintenance of healed EE. KAPIDEX (30 mg and 60 mg) is the first proton pump inhibitor with a Dual Delayed Release (DDR) formulation designed to provide two separate releases of medication.
The details can be read here.
No comments:
Post a Comment